Lichtenfeld: We can do the science, detect ctDNA - but need to ask the hard questions about what detection means #TRICON
5:25pm March 8th 2016 via Hootsuite
Lichtenfeld: Melanoma treatment didn't really change until 2010. Jimmy Carter: don't know what it means he's stopping trtmt #TRICON
5:23pm March 8th 2016 via Hootsuite
Lichtenfeld: Melanoma science:targeted therapies are terrific, but many pts can't get that therapy. And 60% don't respond. #TRICON
5:22pm March 8th 2016 via Hootsuite
Lichtenfeld: Just b/c we can measure something, doesn't mean we should do it. NIPS: sens, spec, and whether physicians understand it #TRICON
5:21pm March 8th 2016 via Hootsuite
Lichtenfeld: The discovery science 'is terrific'; but 'the application science remains far behind'. #TRICON
5:20pm March 8th 2016 via Hootsuite
Lichtenfeld: We know a lot of overtreatment, and have disabled some. 'We can't let that happen again'. #TRICON
Lichtenfeld: An age of 'hope and hype' - many examples. PSA testing: generations that don't remember life w/o it. #TRICON
5:19pm March 8th 2016 via Hootsuite
Lichtenfeld: Back in 1971: Time magazine had an immunologist on the cover, and how it was going to cure cancer. 40y later... #TRICON
5:16pm March 8th 2016 via Hootsuite
Lichtenfeld: This is 'an exciting time' where investments in infrastructure have been made for decades'. #TRICON
Lichtenfeld: No slides, and 'you can take all the photos of me that you want' #TRICON
5:14pm March 8th 2016 via Hootsuite
J Leonard Lichtenfeld (ACS) What clinical validity and utility means for consumers and clinicians in the new era of genomic medicine #TRICON
Weigman: Reduction of sample input, a lot of capability for RNA, DNA, both genotyping and sequencing (NGS, 3rd gen) #TRICON
4:00pm March 8th 2016 via Hootsuite
Weigman: Most companies 'already have the clinical trial samples to take advantage of these technologies' #TRICON
3:59pm March 8th 2016 via Hootsuite
Weigman:Concludes with complexity of pairing immunotherapy to pt, with multiple assays and multiple mechanisms #TRICON
Weigman: Exhortation: "Practice Safe Tests!" HLA alleles and toxicity; PGx; looking at drug-induced liver toxicity #TRICON
3:57pm March 8th 2016 via Hootsuite
Weigman: Immunoscore, multiplex IHC, response signature, novel drug combinations (on the CRO / backend of the subway map) #TRICON
Weigman: Shows a complex 'subway map' for 'mixed genomic testing', with different preclinical research, data and clin trials, Dx mfr #TRICON
3:56pm March 8th 2016 via Hootsuite
Weigman: Need to consider combination therapies. Figure from '15 Cell https://t.co/UKdUOl2ZJV #TRICON
3:55pm March 8th 2016 via Hootsuite
Weigman: >800 cancer drugs in clinical trials; almost all are targeted at particular gene products. #TRICON
3:54pm March 8th 2016 via Hootsuite
Weigman: "Making personalized Abs for de-camoflauging" cancer cells - "it doesn't get more personalized than that" #TRICON
3:52pm March 8th 2016 via Hootsuite
Weigman: TCR affectged in response to CAR-T. Noval antigen detection - neoantigen work by Van Allen ref https://t.co/SOwK0GjNxA #TRICON
3:51pm March 8th 2016 via Hootsuite
Weigman: Shows data from '14 paper https://t.co/m0K4bxO29R and how gene exp clusters #TRICON
3:47pm March 8th 2016 via Hootsuite
Weigman: Sample input chart, across std and FFPE, across tissues, across applications. ctDNA to RNA-seq; WES to IGVH; HLA to qPCR #TRICON
3:45pm March 8th 2016 via Hootsuite
Weigman: Somatic mutations (including breakpoint and fusion detection); gene expression, germline etc. Existing samples accessable #TRICON
3:44pm March 8th 2016 via Hootsuite
Weigman: Four areas for immuno-onc: Checkpt inh; mutational load; gene exp sig; immune repertoire. #TRICON
3:42pm March 8th 2016 via Hootsuite
Weigman: . immuno-oncology drugs approved; 57 in dev; 250 studies ongoing Shows OS curve '15 NEJM https://t.co/54fdzDp3us #TRICON
3:41pm March 8th 2016 via Hootsuite
Weigman: Mentions IMPACT trial (MSKCC) #TRICON Longitudinal data will show how therapies have performed '15 ref https://t.co/ObecL6MR1q
3:40pm March 8th 2016 via Hootsuite
Weigman: Immune therapies show remarkable resp rates for small populations that are receptive; new clinical trial arms needed #TRICON
3:35pm March 8th 2016 via Hootsuite
Weigman: Larger datasets for drug/gene interactions. Most genomic profiling occurs in late-stage. Single-agents show partial resp #TRICON
3:34pm March 8th 2016 via Hootsuite
Victor Weigman (EA Genomics, Q2 Solutions) Expanding treatment options with genomics-enabled immuno-oncology #TRICON
3:33pm March 8th 2016 via Hootsuite
Umemoto: Does theoretical calculations of PCR efficiency, and dependence on GUSB presumed 100% eff. BCR-ABL1 about 89% #TRICON
3:06pm March 8th 2016 via Hootsuite
RT @TriMetisMem: Excel is NOT a Database! #TRICON https://t.co/B7cEape8g4
3:02pm March 8th 2016 via Hootsuite
Umemoto: WHO freeze-dried ref panel; slope not as close (0.964 vs 1.0507) but different RT conditions (input RNA 500ng vs 1ug) #TRICON
3:01pm March 8th 2016 via Hootsuite
Umemoto: Used serial dil of K562 total RNA; GUSB control gene; dilution shows very good linearity cp to WHO ref data #TRICON
2:59pm March 8th 2016 via Hootsuite
Umemoto: d form: 1020 +/-90; measured 749.8 +/- 20, believe 'certified value is closer to 800' #TRICON
2:58pm March 8th 2016 via Hootsuite
Umemoto: Used ERM-AD623 e/f materials, has BRC, ABL1, GUSB genes; 104.0 +/-10; meas 102.1 +/- 11.6 #TRICON
2:57pm March 8th 2016 via Hootsuite
Umemoto: Reviews dPCR, they use Thermo's QuantStudio3D (or rather @appliedbio) #TRICON
2:56pm March 8th 2016 via Hootsuite
Umemoto: Reviews 'enormous effort expended' to achieve int'l standardization, with conversion factors for 2d calibrators #TRICON
2:55pm March 8th 2016 via Hootsuite
Hirohito Umemoto (Ref Material Inst, Yokohama) Standardization on measuring BCR-ABL1 transcripts using dPCR based on WHO #TRICON
2:54pm March 8th 2016 via Hootsuite
Cree:Q:Commutability of EQA materials? A:Tend to send FFPE materials, 'as close as possible'. Have used cell lines 'a headache' #TRICON
2:53pm March 8th 2016 via Hootsuite
Cree: Points to this '11 BMJ Cancer https://t.co/j2vXNc2JfD for cancer screening #TRICON
2:52pm March 8th 2016 via Hootsuite
Cree:Referred to this ImPACT tool for cost analysis for cancer testing https://t.co/RVEP6cLHnx #TRICON
2:49pm March 8th 2016 via Hootsuite
Cree: 3 FDA-approved methods for KRAS: Idylla, Therascreen, Cobas. Similar LoD at 5%. #TRICON
2:44pm March 8th 2016 via Hootsuite
Huggett: PCR primers <150 for FFPE, '<100 is even better'. PCR isn't comprehensive, simple to setup, Idylla is very simple #TRICON
2:41pm March 8th 2016 via Hootsuite
Cree: Meta-analysis '15 only 20% 'New RAS total' https://t.co/cqlPTdS1I0 Suggests 'extended RAS' #TRICON
2:36pm March 8th 2016 via Hootsuite
Cree:But the pathway is targeted; In CRC, 20.9K KRAS in COSMIC, but shows the pie-chart; NRAS only 279. #TRICON
2:34pm March 8th 2016 via Hootsuite
Cree: Large hospital in midlands, catchment of 2.5M. RAS: a rat sarcoma gene, driver growth mutations, no drugs that target #TRICON
2:32pm March 8th 2016 via Hootsuite
Ian Cree (Coventry Univ) Diagnostic RAS mutation analysis by PCR #TRICON
2:31pm March 8th 2016 via Hootsuite
Huggett:Q:Related to microRNA meas? A: Separate biological var but also technical var. #TRICON
2:29pm March 8th 2016 via Hootsuite
Huggett: Rec's '13 Digital MIQE Guidelines https://t.co/BCqCzKO1vU Thanks the digital PCR mfrs, and names them (Patricia Hederich) #TRICON
2:27pm March 8th 2016 via Hootsuite
